Advertisement
Advertisement
U.S. Markets open in 3 hrs 51 mins
Advertisement
Advertisement
Advertisement
Advertisement

SINO BIOPH.SUBDIV.HD-,025 (SMZ1.MU)

Munich - Munich Delayed Price. Currency in EUR
0.54600.0000 (0.00%)
As of 08:05AM CET. Market open.
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.5460
Open0.5460
Bid0.5252 x N/A
Ask0.5442 x N/A
Day's Range0.5460 - 0.5460
52 Week Range0.4444 - 0.6410
Volume410
Avg. Volume105
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    invoX Pharma and F-star Therapeutics issue Joint Statement

    LONDON, Jan. 26, 2023 (GLOBE NEWSWIRE) -- invoX Pharma (“invoX”), a wholly owned subsidiary of Sino Biopharmaceutical Limited (“Sino Biopharm”) (HKEX 1177 HK), and F-star Therapeutics, Inc. (“F-star”) (NASDAQ:FSTX), today issued the following statement regarding their pending transaction in response to a media report: The parties continue working together in active discussions with the Committee on Foreign Investment in the United States (“CFIUS”) about the terms of a mitigation agreement to add

  • Reuters

    China's CanSinoBIO H1 revenue drops on weaker COVID shot demand

    China's CanSino Biologics reported a 69.5% drop in revenue for the first six months versus a year ago, joining global and domestic COVID-19 vaccine makers affected by waning demand for their shots. The decline from 2.06 billion yuan ($299.8 million) to 629.8 million yuan was mainly driven by weaker COVID vaccine demand as growth in global uptake slowed and price changes of CanSinoBIO's products, the firm said in a company filing published on Sunday. CanSinoBIO, which sells a one-dose shot in countries including China and Mexico and is seeking approval for an inhaled version of the vaccine, said half-year net profit dropped by 98.7% year-on-year.

  • Zacks

    F-star (FSTX) Stock Rises on Buyout Offer From Sino Biopharm

    Sino Biopharmaceutical, through its wholly-owned subsidiary, is set to acquire F-star (FSTX) for $7.12 per share in cash. The transaction is likely to close by second-half 2022.

Advertisement
Advertisement